• Something wrong with this record ?

Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone

J. Markova, D. Kahraman, C. Kobe, M. Skopalova, H. Mocikova, K. Klaskova, K. Dedeckova, HT. Eich, B. Böll, M. Dietlein, T. Kozak,

. 2012 ; 53 (1) : 64-70.

Language English Country England, Great Britain

Document type Journal Article

The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-deoxy-d-glucose (FDG)-PET scan was performed after four cycles (PET-4), on completion of chemotherapy after 6/8 cycles (PET-6/8) and 3 months after the completion of chemotherapy (PET 3-months). Median follow-up was 55 months. The negative predictive value (NPV) for PET-4, PET-6/8 and PET 3-months was 98%, 95% and 97%, respectively. The 4-year progression-free survival (PFS) for PET-4 negative (n = 51) and PET-4 positive (n = 18) patients was 96% and 78%, respectively (p = 0.016). The 4-year PFS for PET-6/8 negative (n = 59) and PET-6/8 positive (n = 9) patients was 95% and 78%, respectively (p = 0.046). Patients with a large mediastinal mass constituted nearly all of the PET-4 positive (16/18) and PET-6/8 positive (8/9) patients. After radiotherapy of PET-6/8 positive patients, PET 3-months was negative in 64 (97%) and positive in two (3%) patients. PET 3-months after the end of chemotherapy was of limited value when the interim PET-4 was negative. Interim PET after four cycles of bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) is a strong prognostic marker for PFS in advanced HL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12024420
003      
CZ-PrNML
005      
20121128065108.0
007      
ta
008      
120815s2012 enk f 000 0#eng||
009      
AR
024    7_
$a 10.3109/10428194.2011.603444 $2 doi
035    __
$a (PubMed)21740300
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Marková, Jana $7 xx0143313 $u Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic. markova@fnkv.cz
245    10
$a Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone / $c J. Markova, D. Kahraman, C. Kobe, M. Skopalova, H. Mocikova, K. Klaskova, K. Dedeckova, HT. Eich, B. Böll, M. Dietlein, T. Kozak,
520    9_
$a The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-deoxy-d-glucose (FDG)-PET scan was performed after four cycles (PET-4), on completion of chemotherapy after 6/8 cycles (PET-6/8) and 3 months after the completion of chemotherapy (PET 3-months). Median follow-up was 55 months. The negative predictive value (NPV) for PET-4, PET-6/8 and PET 3-months was 98%, 95% and 97%, respectively. The 4-year progression-free survival (PFS) for PET-4 negative (n = 51) and PET-4 positive (n = 18) patients was 96% and 78%, respectively (p = 0.016). The 4-year PFS for PET-6/8 negative (n = 59) and PET-6/8 positive (n = 9) patients was 95% and 78%, respectively (p = 0.046). Patients with a large mediastinal mass constituted nearly all of the PET-4 positive (16/18) and PET-6/8 positive (8/9) patients. After radiotherapy of PET-6/8 positive patients, PET 3-months was negative in 64 (97%) and positive in two (3%) patients. PET 3-months after the end of chemotherapy was of limited value when the interim PET-4 was negative. Interim PET after four cycles of bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) is a strong prognostic marker for PFS in advanced HL.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bleomycin $x aplikace a dávkování $7 D001761
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a etoposid $x aplikace a dávkování $7 D005047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorodeoxyglukosa F18 $x diagnostické užití $7 D019788
650    _2
$a následné studie $7 D005500
650    _2
$a Hodgkinova nemoc $x diagnóza $x farmakoterapie $x radioizotopová diagnostika $7 D006689
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pozitronová emisní tomografie $x metody $7 D049268
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a prokarbazin $x aplikace a dávkování $7 D011344
650    _2
$a prognóza $7 D011379
650    _2
$a radiofarmaka $x diagnostické užití $7 D019275
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kahraman, Deniz
700    1_
$a Kobe, Carsten
700    1_
$a Skopalová, Magdaléna $7 xx0137935
700    1_
$a Móciková, Heidi, $d 1964- $7 mzk2009517509
700    1#
$a Klásková, Kateřina. $7 _AN051492
700    1_
$a Dědečková, Kateřina $7 xx0063670
700    1_
$a Eich, Hans-Theodor
700    1_
$a Böll, Boris
700    1_
$a Dietlein, Markus
700    1_
$a Kozák, Tomáš, $d 1963- $7 xx0021767
773    0_
$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 53, č. 1 (2012), s. 64-70
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21740300 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120815 $b ABA008
991    __
$a 20121128065143 $b ABA008
999    __
$a ok $b bmc $g 946568 $s 781748
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 53 $c 1 $d 64-70 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
LZP    __
$a Pubmed-20120815/12/02

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...